Orexigen Therapeutics

Orexigen Therapeutics is a public American pharmaceutical company focused on development of treatments for obesity.[1] The company is based in La Jolla, California and was established by Eckard Weber in 2002.[1] As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX.[1]

Orexigen Therapeutics, Inc.
TypePublic
Founded2002 (2002)
FounderEckard Weber
HeadquartersLa Jolla, California, U.S.
Websitewww.orexigen.com

The company has a single product, Contrave, approved for use in the United States in 2014.[2][3] Contrave was designed not only to curb hunger but also reduce cravings.[3] Observation of the market performance of Qsymia and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering.[2]

Orexigen declared bankruptcy in 2018 and was sold to Nalpropion.[4][5]

References
  1. "OREX Key Statistics". MarketWatch. Retrieved 12 September 2014.
  2. Osborne, Spencer (7 October 2014). "Orexigen On A Tear - In The Wrong Direction". Seeking Alpha.
  3. "Orexigen Enters into Agreement to Sell Company to Newly Formed Entity Nalpropion Pharmaceuticals". BioSpace. Retrieved 2020-06-15.
  4. "U.S. drugmaker Orexigen files for Chapter 11 bankruptcy". Reuters. 2018-03-12. Retrieved 2019-07-30.
  5. "No magic pill for obesity: Orexigen files for bankruptcy". BioPharma Dive. Retrieved 2020-06-15.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.